Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Primary Myelofibrosis 9Myeloproliferative Disorders 5Polycythemia Vera 4Thrombocythemia, Essential 3Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thalassemia 1Pancreatic Neoplasms 1Other Cancer 1Mesothelioma 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammatory Breast Neoplasms 1Hypereosinophilic Syndrome 1Graft vs Host Disease 1Exanthema 1

Interventions

Paclitaxel 6Cyclophosphamide 5pembrolizumab 3Taxes 3Specimen Handling 3Doxorubicin 3Carboplatin 3eribulin 2Trastuzumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sargramostim 1ruxolitinib 1pertuzumab 1onvansertib 1olaparib 1cobimetinib 1atezolizumab 1X-Rays 1Therapeutics 1Radiotherapy 1Radiation 1Panitumumab 1Palliative Care 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Gonadotropin-Releasing Hormone 1Exercise Test 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Inflammatory Breast Neoplasms × ruxolitinib × Clear all
NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
23 enrolled 18 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡